Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Esophageal motility disorders.

Provencher DM.

JAAPA. 2017 Apr;30(4):47-48. doi: 10.1097/01.JAA.0000513347.75125.9d. No abstract available.

PMID:
28350732
2.

Hormonal and reproductive factors and the risk of ovarian cancer.

Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb WH, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J.

Cancer Causes Control. 2017 May;28(5):393-403. doi: 10.1007/s10552-016-0848-9. Epub 2017 Jan 19.

PMID:
28102526
3.

Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.

Pelletier MP, Trinh VQ, Stephenson P, Mes-Masson AM, Samouelian V, Provencher DM, Rahimi K.

Hum Pathol. 2017 Apr;62:33-39. doi: 10.1016/j.humpath.2016.10.023. Epub 2016 Nov 15.

PMID:
27864117
4.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM.

Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.

PMID:
27546885
5.

Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

Te Grootenhuis NC, van der Zee AG, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, Baldwin PJ, Gaarenstroom KN, van Dorst EB, Trum JW, Slangen BF, Runnebaum IB, Tamussino K, Hermans RH, Provencher DM, de Bock GH, de Hullu JA, Oonk MH.

Gynecol Oncol. 2016 Jan;140(1):8-14. doi: 10.1016/j.ygyno.2015.09.077. Epub 2015 Sep 30.

PMID:
26428940
6.

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN.

Oncol Lett. 2015 Jun;9(6):2787-2790. Epub 2015 Apr 20.

7.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S9-13. doi: 10.1097/IGC.0000000000000257. Review.

PMID:
25341587
8.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
9.

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7. doi: 10.1097/IGC.0000000000000281. Review.

PMID:
25341584
10.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282. Review.

PMID:
25341581
11.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249. Review.

PMID:
25341579
12.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.

Reed NS, Pautier P, Åvall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S30-4. doi: 10.1097/IGC.0000000000000293. Review.

PMID:
25341577
13.

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8. doi: 10.1097/IGC.0000000000000262. Review.

PMID:
25341572
14.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.

PMID:
24950985
15.

An update on nonalcoholic fatty liver disease.

Provencher DM.

JAAPA. 2014 Jul;27(7):18-22. doi: 10.1097/01.JAA.0000450801.19545.93.

PMID:
24901731
16.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
17.

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.

Mol Oncol. 2013 Jun;7(3):513-30. doi: 10.1016/j.molonc.2012.12.006. Epub 2013 Jan 16.

18.

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.

Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN.

Int J Oncol. 2013 Mar;42(3):912-20. doi: 10.3892/ijo.2013.1797. Epub 2013 Jan 23.

PMID:
23354471
19.

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN.

BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5.

20.

[Early detection of ovarian cancer: tomorrow? A review].

Chene G, Penault-Llorca F, Robin N, Cayre A, Provencher DM, Dauplat J.

J Gynecol Obstet Biol Reprod (Paris). 2013 Feb;42(1):5-11. doi: 10.1016/j.jgyn.2012.10.011. Epub 2012 Nov 22. Review. French.

Supplemental Content

Loading ...
Support Center